Urogen Pharma Soars 4.34% Post-Employee RSU Grant!

viernes, 6 de junio de 2025, 5:38 pm ET1 min de lectura
URGN--
Urogen Pharma Ltd. rose 4.34% in after-hours trading, with the company announcing the grants of inducement restricted stock units (RSUs) to 27 new employees. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the continued development of the Company’s pipeline. Up to 118,000 ordinary shares of UroGenURGN-- are issuable upon the vesting and settlement of the RSUs.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios